BULKY DOCUMENTS
`(exceeds 300 pages)
`
`Proceeding]Serial No: 9/] E S E) 03
`
`Filed:
`
`[V/3‘ 09
`
`Title:
`
`[!O£u‘g§ OP
`
`£9, //‘r‘MC—2
`
`Part _l_ o_fa_
`
`

`
`I HEREBY CERTIFY THAT HIS
`
`6 'I' SPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS
`
`
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD
`
`BIOGEN IDEC INC.
`
`Opposera
`
`v.
`
`Opposition No. 91,165,803
`
`BIOGENESIS NUTRACEUTICALS, INC.
`Applicant.
`
`NOTICE OF RELIANCE
`
`Honorable Commissioner for Trademarks
`P.O. Box 1451
`
`Alexandria, VA 22313-1451
`
`Dear Commissioner:
`
`Pursuant to T.B.M.P. §§704.03(b)(l)(B) and 704.08, and 37 C.F.R. §2.122(e),
`Opposer hereby gives notice that it intends to rely on the third-party registrations evidenced by
`copies of the printouts from the US PTO website attached hereto, and corresponding copies of
`pages from the Physician’s Desk Reference For Prescription Drugs and Physician’s Desk
`Reference For Nonprescription Drugs attached hereto, which are available to the general public
`in libraries or of general circulation among members of the public, or that segment of the public
`which is relevant to this proceeding, listed below which are relevant to show that companies
`(directly or through their affiliates or subsidiaries) manufacture, distribute, sell and/or promote
`both prescription and non-prescription pharmaceutical preparations and medicines.
`
`
`
`W eth Pharmaceuticals:
`
`3%£a
`
`Nonrescrition
`
`
`
`
`
`
`
`AA
`
`
`
`
`
`
`
`DMEAST #9555200 V1
`
`11.13—2006
`U.S. Patent 8. TMOfcITM Mail Rcpt D1 #22
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Nonrescrition
`
`Nonrescrition
`
`Prescrition
`
`Nonrescrition
`
`Nonrescrition
`
`Novartis:
`
`
`
`
`
`
`
`Glaxosmith kline:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Aumentin
`
`Prescrition
`
`
`
`
`
`
`
`
`
`
`
`T
`
`Respectfully submitted,
`
`
`
`SPAHR ANDREWS & INGERSOLL, LLP
`BALLA
`1735 Market Street — 51“ Floor
`
`Philadelphia, PA 19103
`(215)665-8500
`ATTORNEYS FOR OPPOSER
`
`DMEAST #9555200 V1
`
`2
`
`

`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a true and correct copy of the attached Notice of
`Reliance filed with U.S. Trademark Trial and Appeal Board was served on counsel for the
`Applicant at the addresses and on the date listed below via the United States Postal Service as
`First Class Mail, postage pre-paid:
`
`Paul Richard Brown, Esquire
`BERESFORD BOOTH PLLC
`
`145 Third Avenue South, Suite 200
`Edmonds, WA 98020
`pau1b@beresford1aw.com
`
`Lawrence Graham, Esquire
`BLACK LOWE & GRAHAM
`
`701 Fifth Avenue, Suite 4800
`Seattle, WA 98104
`graham@blacklaw.com
`
`Dated: MM. 7 ,2006
`
`d
`
`«
`
`—.
`
`DMEAST #9555200 v1
`
`3
`
`

`
`Latest Status Info
`
`Page 1 of 2
`
`Thank you for your request. Here are the latest results from the TARR web server.
`
`This page was generated by the TARR system on 2006-06-27 20:24:56 ET
`
`Serial Number: 71477895 As_§gi;ment Infomation
`
`Registration Number: 416252 Assignment I_nformatiQ_r_1_
`
`Mark (words only): BENADRYL
`
`Standard Character claim: No
`
`Current Status: This registration has been renewed.
`
`Date of Status: 2005- 10-05
`
`Filing Date: 1944-12-23
`
`Transformed into a National Application: No
`
`Registration Date: 1945-09-04
`
`Register: Principal
`
`Law Office Assigned: (NOT AVAILABLE)
`
`If you are the applicant or applicant's attorney and have questions about this file, please contact the
`Trademark Assistance Center at TradeinarkA_s_si_staneeCenter@uspt_o:goy
`
`Current Location: MID -TMO Law Office 110 - Docket Clerk
`
`Date In Location: 2006-02-13
`
`
`
`LAST APPLICANT(S)/OWNER(S) OF RECORD
`
`1. WARNER-LAMBERT COMPANY LLC
`
`Address:
`
`WARNER—LAMBERT COMPANY LLC
`201 TABOR ROAD
`
`MORRIS PLAINS, NJ 07950
`United States
`
`Legal Entity Type: Ltd Liab C0
`State or Country Where Organized: Delaware
`
`GOODS ANDIOR SERVICES
`
`U.S. Class: 018 {International Class 005)
`Class Status: Active
`
`http://tarr.uspto.gov/servIet/tarr?regser=serial&entry=71477895
`
`6/27/2006
`
`

`
`Latest Status Info
`
`Page 2 of 2
`
`PHARMACEUTICAL PREPARATIONS CONTAINING DIPHENHYDAMINE HYDROCHLORIDE
`Basis: 1(a)
`First Use Date: 1944-11-27
`
`First Use in Commerce Date: 1944-1 1-27
`
`ADDITIONAL INFORMATION
`
`
`(NOT AVAILABLE)
`
`MADRID PROTOCOL INFORMATION
`
`
`NOT AVAILABLE)
`
`
`
`PROSECUTION HISTORY
`
`2005-] 1-15 - Undeliverable Mai] - No Action Taken
`
`2005-] 1-09 - Undeliverable Mail - No Action Taken
`
`2005-10-17 - PAPER RECEIVED
`
`2005-10-05 - Third renewal 10 year
`
`2005-10-05 - Section 8 (10-year) accepted! Section 9 granted
`
`2005-09-29 - Assigned To Paralegal
`
`2005-08-18 - Combined Section 8 (10-year)/Section 9 filed
`
`2005-08-18 - Combined Section 8 (10-year)/Section 9 filed
`
`2005-08-18 - TEAS Section 8 & 9 Received
`
`1985-09-24 - Second renewal
`
`1985-03-22 - Section 9 filed/check record for Section 8
`
`
`
`CORRESPONDENCE INFORMATION
`
`Correspondent
`T. D. MOLITERNO, LEGAL DIVISION
`WARNER-LAMBERT COMPANY
`201 TABOR ROAD
`
`MORRIS PLAINS, NJ 07950
`
`
`
`http://tarnuspto.gov/servlet/ta1T?regser=serial&entry=71477895
`
`6/27!2006
`
`

`
`Page 1
`
`6 of 192 DOCUMENTS
`
`Copyright 2005 Micromedex, inc. All Rights Reserved
`Physician's Desk Reference for Non—Prescription Drugs
`
`Benadryl Allergy Ultratab Tablets(Pfizer Consumer Healthcare)
`
`BODY:
`
`Drug Facts:
`
`Active Ingredient:
`(in each capsule)
`
`Purpose:
`
`Diphenhydramine HCl
`25 mg ..................................... .. Antihistamine
`
`Uses:
`
`temporarily relieves these symptoms due to hay fever or other upper respiratory allergies:
`runny nosesneezingitchy, watery eyesitching of the nose or throat ztemporarily relieves these symptoms due to the
`common cold:
`
`runny nosesneezing
`
`Warnings:
`
`Do not use with any other product containing diphenhydramine, even one used on skin.
`
`Ask a doctor before use if you have:
`
`glaucomatrouble urinating clue to an enlarged prostate glanda breathing problem such as emphysema or chronic
`bronchitis
`
`Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers
`
`When using this product:
`
`marked drowsiness may occuravoid alcoholic drinksalcohol, sedatives, and tranquilizers may increase drowsinessbe
`careful when driving a motor vehicle or operating machineryexcitability may occur, especially in children
`
`If pregnant or breast-feeding, ask a health professional before use.
`
`Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
`
`Directions:
`
`take every 4 to 6 hoursdo not take more than 6 doses in 24 hours
`
`adults and children 12 years of age and
`over
`
`25 mg to 50 mg (1 to 2 capsules)
`
`children 6 to under 12 years of age
`
`12.5 mg ** to 25 mg (1 capsule)
`
`é"LexisNexis"
`
`é"LexisNexis"
`
`é""LexisNexis*"
`
`

`
`Physician's Desk Reference for Non—Prescription Drugs
`
`Page 2
`
`ask a doctor
`children under 6 years of age
`**12.5 mg dosage strength is not available in this package. Do not
`attempt to break capsules.
`
`Other Information:
`
`store at 59 deg.
`
`to 77 deg. F in a dry placeprotect from light
`
`Inactive Ingredients: Capsules: D&C red no. 28, FD&C blue no. 1, FD&C red no. 3, FD&C red no. 40, gelatin,
`glyceryl monooleate, lactose, magnesium stearate, and titanium dioxide. Printed with black edible ink.
`
`Tablets: candelilla wax, crospovidone, dibasic calcium phosphate dihydrate, D&C red no. 27 aluminum lake,
`hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, pregelatinized
`starch, stearic acid, and titanium dioxide.
`
`Questions? call 1-800-524-2624 (English/Spanish), weekdays, 9 AM-5 PM EST
`
`How Supplied: Benadryl tablets are supplied in boxes of 24 and 48, bottle of 100; capsules are supplied in boxes of
`24 and 48.
`
`PRODUCT PI-lO'TO(S): NOTE: These photos can be used only for identification by shape, color, and imprint. They
`do not depict actual or relative size.
`
`The product samples shown here have been supplied by the manufacturer and reproduced in full color by PDR as a
`quick—reference identification aid. While every effort has been made to assure accurate reproduction, please remember
`that any visual identification should be considered preliminary.
`In cases of poisoning or suspected overdosage, the
`drug's identity should be verified by chemical analysis.
`See Image
`
`LANGUAGE: ENGLISH
`
`LOAD-DATE: February 11, 2005
`
`6" LexisNexis'"
`
`LexisNexis"
`
`LexisNexis"'
`
`

`
`Latest Status Info
`
`Page I of 3
`
`Thank you for your request. Here are the latest results from the TARR web server.
`
`This page was generated by the TARR system on 2006-06-27 20:25:36 ET
`
`Serial Number: 74200311 Assigment I_njqrrnation
`
`Registration Number: 1803595 Assignment Information
`
`Mark
`
`Cortizone-10
`
`(words only): CORTIZONE-10
`
`Standard Character claim: No
`
`Current Status: This registration has been renewed.
`
`Date of Status: 2003-05-25
`
`Filing Date: 1991-09-03
`
`Transformed into a National Application: No
`
`Registration Date: 1993-11-09
`
`Register: Principal
`
`Law Office Assigned: LAW OFFICE 1 1
`
`If you are the applicant or applicant's attorney and have questions about this file, please contact the
`Trademark Assistance Center at T_ra_deI_na,I;kAssistflc§Qen_ter@usptg.g0v
`
`Current Location: 900 -File Repository (Franconia)
`
`Date In Location: 2003-06-03
`
`
`
`LAST APPLICANT(S)f0WNER(S) OF RECORD
`
`
`1. PFIZER INC.
`1
`i Address:
`PFIZER INC.
`
`235 EAST 42ND STREET
`
`http://tarnuspto.gov/servlet/tarr?regser=seria1&entry=7-420031 1
`
`6/27/2006
`
`

`
`Latest Status Info
`
`Page 2 of 3
`
`NEW YORK, NY 10017
`United States
`
`Legal Entity Type: Corporation
`State or Country of Incorporation: Delaware
`
`GOODS ANDIOR SERVICES
`
`International Class: 005
`Class Status: Active
`
`medication for the relief of minor skin irritations
`Basis: 1(a)
`First Use Date: 1992-09-29
`
`First Use in Commerce Date: 1992-09-29
`
`ADDITIONAL INFORMATION
`
`Prior Registration Number(s):
`1 562987
`
`
`
`MADRID PROTOCOL INFORMATION
`
`(NOT AVAILABLE)
`
`
`
`2003-0'5-2-5 -"First renewal 1o"ye;é;{
`
`I
`
`PROSECUTION HISTORY
`
`2003-05-25 - Section 8 (10-year) accepted! Section 9 granted
`
`2003-01-27 - Combined Section 8 (10-year)/Section 9 filed
`
`2003-01-27 - PAPER RECEIVED
`
`1999-08-01 - Section 8 (6-year) accepted & Section 15 acknowledged
`
`1999-02-23 - Section 8 (6-year) and Section 15 Filed
`
`1993-1 1-09 - Registered - Principal Register
`
`1993-08-13 - Allowed for Registration - Principal Register (SOU accepted)
`
`1993-07-21 - Statement of use processing complete
`
`1992-12-28 - Amendment to Use filed
`
`1993-07-01 - Reinstated
`
`1993-02-26 - Abandonment - No use statement filed
`
`http://tarr.uspto.gov/servlet/tarr‘?regser=serial&entry=-7420031 I
`
`6/27/2006
`
`

`
`Latest Status Info
`
`Page 3 of 3
`
`1992-08-25 - Notice of allowance - mailed
`
`1992-06-02 - Published for opposition
`
`1992-05-01 - Notice of publication
`
`1991-12-09 - Approved for Pub - Principal Register (Initial exam)
`
`1991-12-04 - Assigned To Examiner
`
`CORRESPONDENCE INFORMATION
`,, m_____ _
`
`Correspondent
`JANE UNGARO (Attorney of record)
`
`JANE UNGARO
`
`PFIZER INC
`201 TABOR ROAD
`
`MORRIS PLAINS, NJ 07950
`
`http://tarr.uspto.gov/servlet/tarr?regse1=seria1&entry=7420031 1
`
`6/27/2006
`
`

`
`Page 3
`
`46 of 192 DOCUMENTS
`
`Copyright 2005 Micromedex, Inc. All Rights Reserved
`Physician's Desk Reference for Non—Prescription Drugs
`
`Cortizone 10 Creme(Pfizer Consumer Healthcare)
`
`B ODY:
`
`Drug Facts
`
`Active Ingredient: Purpose:
`
`Hydrocortisone 1% .................. .. Anti—itch
`
`Uses:
`
`temporarily relieves itching of minor skin irritations, inflammation, and rashes due tozeczemainsect bitescosmet—
`icspsoriasisdetergentssoapspoison ivy, oak, sumacjewelryseborrheic dermatitisand for external anal and genital
`itching
`
`other uses of this product should be only under the advice and supervision of a doctor
`
`Warnings:
`
`For external use only
`
`Do no use
`
`for the treatment of diaper rash. Consult a doctor.in the genital area if you have a vaginal discharge. Consult a doctor.
`
`When using this product
`
`avoid contact with the eyesdo not exceed the recommended daily dosage unless directed by a doctordo not put directly
`in rectum by using fingers or any mechanical device
`
`Stop use and ask a doctor if
`
`rectal bleeding occurscondition worsens, or if symptoms persist for more than 7 days or clear up and occur again
`within a few days, and do not begin use of any other hydrocortisone product unless you have asked a doctor
`
`Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
`
`Directions:
`
`adults and children 2 years of age and older:apply to affected area not more than 3 to 4 times dailychildren under 2
`years of age: do not use, ask a doctor
`
`for external anal and genital itching, adultszwhen practical, clean the affected area with mild soap and warm water and
`rinse thoroughlygently dry by patting or blotting with toilet tissue or a soft cloth before applyingapply to affected area
`not more than 3 to 4 times dailychildren under 12 years of age: ask a doctor
`
`Other lnforrnation: store at 15 deg.
`
`to 30 deg. C (59 deg.
`
`to 86 deg. F)
`
`é"LexisNexis'"
`
`é"'LexisNexis*"
`
`é"'LexisNexis"*
`
`

`
`Physician's Desk Reference for Non—Prescription Drugs
`
`Page 4
`
`Inactive Ingredients: aloe barbadensis gel, aluminum sulfate, calcium acetate, cetearyl alcohol, glycerin, light mineral
`oil, maltodextrin, methylparaben, potato dextrin, propylparaben, purified water, sodium cetearyl sulfate, sodium
`lauryl sulfate, white petrolatum, and white wax
`
`Questions? call 1-800-223-0182, Monday to Friday, 9 AM - 5 PM EST
`
`How Supplied: CORTIZONE 10(R) creme:
`
`.5 oz.,
`
`1 oz. and 2 oz. tubes.
`
`PRODUCT PHOIU(S): N01"E: These photos can be used only for identification by shape, color, and imprint. They
`do not depict actual or relative size.
`
`The product samples shown here have been supplied by the manufacturer and reproduced in full color by PDR as a
`quick—reference identification aid. While every effort has been made to assure accurate reproduction, please remember
`that any visual identification should be considered preliminary.
`In cases of poisoning or suspected overdosage, the
`drug's identity should be verified by chemical analysis.
`See Image
`
`LANGUAGE: ENGLISH
`
`LOAD-DATE: February 11, 2005
`
`6" LexisNexis“
`
`LexisNexis'"
`
`LexisNexis‘"
`
`

`
`Latest Status Info
`
`Page 1 of 3
`
`Thank you for your request. Here are the latest results from the TARR web server.
`
`This page was generated by the TARR system on 2006-06-27 20:26:50 ET
`
`Serial Number: 73426051 Assignmentjnfqnnation
`
`Registration Number: 1293844 Assignment Lnfonnation
`
`Mark
`
`Nosolcrom
`
`(words only): NASALCROM
`
`Standard Character claim: No
`
`Current Status: This registration has been renewed.
`
`Date of Status: 2004-09-20
`
`1 Filing Date: 1983-05-16
`
`Transformed into a National Application: No
`
`Registration Date: 1984-09-1 1
`
`Register: Principal
`
`Law Office Assigned: (NOT AVAILABLE)
`
`If you are the applicant or applicant's attorney and have questions about this file, please contact the
`Trademark Assistance Center at Tra_de_markAssistanc_¢£enter@uspto.gox
`
`Current Location: 900 -File Repository (Franconia)
`
`Date In Location: 2004-09-24
`
`
`
`LAST APPLICANT(S)/OWNER(S) or RECORD
`
`1. Pharmacia & Upjohn Company
`
`Address:
`
`Pharmacia & Upjohn Company
`301 Henrietta Street
`
`http://tarr.uspto.govlservlet/tarr?regser=serial&entry=73426051
`
`6/27/2006
`
`1 ‘
`
`

`
`Latest Status Info
`
`Kalamazoo, MI 49001
`United States
`
`Legal Entity Type: Corporation
`State or Country of Incorporation: Delaware
`
`Page 2 of 3
`
`GOODS ANDIOR SERVICES
`-
`
`International Class: 005
`Class Status: Active
`
`Anti-Allergic Solution for the Prevention and Treatment of Allergic Rhinitis
`Basis: 1(a)
`First Use Date: 1982-12-20
`
`First Use in Commerce Date: 1982-12-20
`
`_ wM_ __+:
`
`ADDITIONAL INFORMATION
`
`
`Prior Registration Number(s):
`1078233
`1087892
`
`MADRID PROTOCOL INFORMATION
`
`
`(NOT AVAILABLE)
`
`PROSECUTION HISTORY
`
`2004-09-20 - First renewal 10 year
`
`2004-09-20 - Section 8 (10-year) accepted/ Section 9 granted
`
`2004-08-24 - Combined Section 8 (10-year)/Section 9 filed
`
`2004-08-24 — Combined Section 8 (10-year)/Section 9 filed
`
`2004-08-24 - TEAS Section 8 & 9 Received
`
`2004-08-24 — TEAS Change Of Correspondence Received
`
`1994-01-25 - Post Registration action correction
`
`1990-05-15 - Section 8 (6-year) accepted & Section 15 acknowledged
`
`1990-03-29 - Section 8 (6-year) and Section 15 Filed
`
`1984-09-11 - Registered - Principal Register
`
`1984-06-26 - Published for opposition
`
`http://tarr.uspto.gov/serv1et/tarr?regseFseria1&entry=73426051
`
`6/27/2006
`
`

`
`Latest Status Info
`
`Page 3 of 3
`
`|
`
`1984-05-02 - Notice of publication
`
`1984-03-14 - Approved for Pub - Principal Register (Initial exam)
`
`1984-01-20 - Communication received from applicant
`
`1983-12-27 - Non-final action mailed
`
`1983-12-12 - Assigned To Examiner
`
`CORRESPONDENCE INFORMATION
`
`
`
`Correspondent
`Richard A. Friedman
`Pfizer Inc.
`
`Legal Dvision, 56/2
`201 Tabor Road
`
`Morris Plains NJ 07950
`
`Phone Number: 973-385-2259
`Fax Number: 973-385-3117
`
`Domestic Representative
`FROST & JACOBS
`
`
`
`http2//tarr.uspto.gov/servlet/tarr?regseFserial&entry=73426051
`
`6/2 7/2006
`
`

`
`Page 5
`
`93 of 192 DOCUMENTS
`
`Copyright 2005 Micromedex, Inc. All Rights Reserved
`Physician's Desk Reference for Non—Prescription Drugs
`
`NasalCrom Nasal Spray(Pfizer Consumer Healthcare)
`
`BODY:
`
`Description: NASALCROM Nasal Spray contains a liquid formulation of cromolyn sodium that stabilizes mast cells
`that release histamine. NASALCROM is neither an antihistamine nor a decongestant nor a corticosteroid. In addition
`to treating nasal allergy symptoms, it decreases the allergic reaction by reducing the release of histamine, the trigger of
`allergy symptoms, from mast cells. NASALCROM has no known drug interactions and is safe to use with medications
`including other allergy medications.
`
`Active Ingredient:
`
`(per spray) Cromolyn sodium 5.2mg
`
`Indications: To prevent and relieve nasal symptoms of hay fever and other nasal allergies:
`
`runny/itchy nose sneezing allergic stuffy nose
`
`Directions:
`
`parent or care provider must supervise the use of this product by young children. Adults and children 2 years and
`older:
`
`spray once into each nostril. Repeat 3-4 times a day (every 4-6 hours). If needed, may be used up to 6 times a day.
`
`use every day while in contact with the cause of your allergies (pollen, molds, pets, and dust)
`
`to prevent nasal allergy symptoms, use before contact with the cause of your allergies. For best results, start using up
`to one week before contact.
`
`if desired, you can use this product with other medications, including other allergy medications.
`
`children under 2 years: Do not use unless directed by a doctor
`
`Warnings:
`
`Do not use if you are allergic to any of the ingredients
`
`Ask a doctor before use if you have fever discolored nasal discharge sinus pain wheezing
`
`When using this product it may take several days of use to notice an effect. Your best effect may not be seen for 1
`to 2 weeks brief stinging or sneezing may occur right after use do not use to treat sinus infection, asthma, or cold
`symptoms do not share this bottle with anyone else as this may spread germs
`
`Stop use and ask a doctor if
`
`shortness of breath, wheezing, or chest tightness occurs hives or swelling of the mouth or throat occurs your symptoms
`worsen you have new symptoms your symptoms do not begin to improve within two weeks
`
`you need to use more than 12 weeks
`
`6'" LexisNexis'"
`
`LexisNexis'"
`
`LexisNexis’“
`
`

`
`Physician's Desk Reference for Non-Prescription Drugs
`
`Page 6
`
`If pregnant or breast feeding ask a health professional before use.
`
`Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
`
`Inactive Ingredients: benzalkonium chloride, edetate disodium, purified water
`
`How Supplied: NASALCROM Nasal Spray is available in l3mL (100 metered sprays) and 26mL (200 metered sprays)
`sizes
`
`Store between 20 deg.-25 deg. C (68 deg.—77 deg. F). Keep away from light.
`
`LANGUAGE: ENGLISH
`
`LOAD-DATE: February 11, 2005
`
`é"'LexisNexis*"
`
`é'"LexisNexis'"
`
`é'"LexisNexis'"
`
`

`
`Latest Status Info
`
`Page 1 of 3
`
`Thank you for your request. Here are the latest results from the TARR web server.
`
`This page was generated by the TARR system on 2006-06-27 20:28:29 ET
`
`Serial Number: 71653424 Assjg_n;n_e11tLInf9nnation
`
`Registration Number: 591597 Assign;ne_nt_ Information
`
`Mark
`
`Rolai
`
`
`
`(words only): ROLAIDS
`
`Standard Character claim: No
`
`Current Status: This registration has been renewed.
`
`Date of Status: 2004-04-13
`
`Filing Date: 1953-09-21
`
`Transformed into a National Application: No
`
`Registration Date: 1954-06-22
`
`Register: Principal
`
`Law Office Assigned: (NOT AVAILABLE)
`
`If you are the applicant or applicant's attorney and have questions about this file, please contact the
`Trademark Assistance Center at Itad,l:m_a1‘_kA$stan_c_fiZ+ente|;@uspto4goy
`
`; Current Location: 900 -File Repository (Franconia)
`
`Date In Location: 2004-04-26
`
`
`LAST APPLICANT(S)/0WNER(S) OF RECORD
`
`1. WARNER-LAMBERT COMPANY LLC
`
`Address:
`
`WARNER-LAMBERT COMPANY LLC
`201 TABOR ROAD
`
`http://tarr.uspto.gov/servlet/tarr‘?regser=serial&entry=71653424
`
`6/27/2006
`
`

`
`Latest Status Info
`
`Page 2 of 3
`
`MORRIS PLAINS, NJ 07950
`United States
`
`Legal Entity Type: Ltd Liab Co
`State or Country Where Organized: Delaware
`
`GOODS AND/OR SERVICES
`
`
`U.S. Class: 018 (International Class 005)
`Class Status: Active
`ANTACID MINTS
`
`Basis: 1(a)
`First Use Date: 1953-08-25
`
`First Use in Commerce Date: 1953-08-25
`
`
`
`ADDITIONAL INFORMATION
`
`
`(NOT AVAILABLE)
`
`
`
`MADRID PROTOCOL INFORMATION
`
`(NOT AVAILABLE)
`
`PROSECUTION HISTORY
`
`
`2004-04-13 - Third renewal 10 year
`
`2004-04-13 - Section 8 (10-year) accepted/ Section 9 granted
`
`2004-03-26 - Combined Section 8 (10-year)/Section 9 filed
`
`2004-03-26 - TEAS Section 8 & 9 Received
`
`1994-07-14 - Second renewal 10 year
`
`I994-06-06 - Section 9 filed/check record for Section 8
`
`1974-06-22 - First renewal
`
`CORRESPONDENCE INFORMATION
`: __ _
`
`
`
`Correspondent
`RICHARD A. FRIEDMAN (Attorney of record)
`
`RICHARD A. FRIEDMAN
`PFIZER INC.
`
`LEGAL DIVISION BUILDING 56/2ND SOUTH
`201 TABOR ROAD
`
`http://tarr.uspto.gov/servlet/tarr'?regsei=serial&entry=7I 653424
`
`6/2 7/2006
`
`

`
`Latest Status Info
`
`MORRIS PLAINS NJ 07950
`
`Page 3 of 3
`
`http://tarr.uspto.gov/serv1etJtarr?regser=serial&entry=71653424
`
`6/27/2006
`
`

`
`Page 7
`
`127 of 192 DOCUMENTS
`
`Copyright 2005 Micromedex, Inc. All Rights Reserved
`Physicia.n's Desk Reference for Non—Prescription Drugs
`
`Rolaids Tablets(Pfizer Consumer Healthcare)
`
`BODY:
`
`Drug Facts:
`
`Active Ingredients
`(in each tablet): Purpose:
`
`Calcium carbonate 550 mg ............... .. Antacid
`
`Magnesium hydroxide 110 mg .......... .. Antacid
`
`Uses:
`
`relieves: heartburn sour stomach acid indigestion upset stomach due to these symptoms
`
`Warnings:
`
`Ask a doctor or pharmacist before use if you are
`
`presently taking a prescription drug. Antacids may interact with certain prescription drugs.do not take more than
`12 tablets in a 24~hour period, or use the maximum dosage for more than 2 weeks, except under the advice and
`supervision of a physician.
`
`Keep out of reach of children.
`
`Directions
`
`chew 2 to 4 tablets, hourly if needed
`
`Other Information:
`
`each tablet contains: calcium 220 mg and magnesium 45 mgstore at 59 deg.
`
`to 77 deg. F in a dry place
`
`Peppermint and Spearmint Flavors: dextrose, flavoring, magnesium stearate, polyethylene
`Inactive Ingredients:
`glycol, pregelatinized starch and sucrose
`
`Cherry Flavor: dextrose, flavoring, magnesium stearate, polyethylene glycol, pregelatinized starch, D&C red no. 27
`aluminum lake, and sucrose
`
`Actions: Rolaids(R) provides rapid neutralization of stomach acid. Each tablet has an acid—neutra1izing capacity of
`14.7 mEq and the ability to maintain the pH of stomach contents at 3.5 or greater for a significant period of time.
`
`Dosage and Administration: Chew 2 to 4 tablets as symptoms occur. Repeat hourly if symptoms return, or as directed
`by a physician.
`
`How Supplied: Rolaids(R) is available in l2—tablet rolls, 3—packs containing three 12-tablet rolls and in bottles
`Containing 150 or 300 tablets.
`
`é'"LexisNexis"* é"‘LexisNexis”
`
`é'"LexisNexis‘"
`
`

`
`Physician's Desk Reference for Non—Prescription Drugs
`
`Page 8
`
`PRODUCT PHOTO(S): NOTE: These photos can be used only for identification by shape, color, and imprint. They
`do not depict actual or relative size.
`
`The product samples shown here have been supplied by the manufacturer and reproduced in full color by PDR as a
`quick—reference identification aid. While every effort has been made to assure accurate reproduction, please remember
`that any visual identification should be considered preliminary.
`In cases of poisoning or suspected overdosage, the
`drug's identity should be verified by chemical analysis.
`
`See Image
`
`LANGUAGE: ENGLISH
`
`LOAD-DATE: February 11, 2005
`
`.
`
`.
`
`»
`
`{
`
`‘-
`
`6'" LexisNexis““
`
`LexisNexis'"
`
`LexisNexis*"
`
`

`
`Latest Status Info
`
`Page 1 of 3
`
`Thank you for your request. Here are the latest results from the TARR web server.
`
`This page was generated by the TARR system on 2006-06-27 20:29:17 ET
`
`Serial Number: 71623397 As_s_ig@ent Information
`
`Registration Number: 565723 Assignment Infotmation
`
`Mark
`
`SUDAFED
`
`(words only): SUDAFED
`
`Standard Character claim: No
`
`Current Status: This registration has been renewed.
`
`Date of Status: 2003-02-10
`
`Filing Date: 1952-01-10
`
`Transformed into a National Application: No
`
`Registration Date: 1 952-10-21
`
`Register: Principal
`
`Law Office Assigned: (NOT AVAILABLE)
`
`‘
`
`If you are the applicant or applicant's attorney and have questions about this file, please contact the
`Trademark Assistance Center at Ir;a;l_ema_1;kAsflt_ance(;enter@uspjo,gmr_
`
`Current Location: 900 -File Repository (Franconia)
`
`Date In Location: 2003-02-1 1
`
`LAST APPLICANT(S)/OWNER(S) OF RECORD
`
`1. WARNER-LAMBERT COMPANY
`
`Address:
`
`WARNER-LAMBERT COMPANY
`
`201 TABOR ROAD LEGAL DIVISION, 56/2
`
`http://tarr.uspto.gov/servlet/tarr?regser=serial&entry=71623397
`
`6/2 7/2006
`
`

`
`Latest Status Info
`
`MORRIS PLAINS, NJ
`United States
`
`Legal Entity Type: Corporation
`State or Country of Incorporation: Delaware
`
`Page 2 of 3
`
`GOODS ANDIOR SERVICES
`
`U.S. Class: 018 (International Class 005)
`Class Status: Active
`
`MEDICINAL PREPARATION INTENDED FOR USE AS A SYMPATI-IOMIMETIC
`
`Basis: 1(a)
`First Use Date: 1951-12-18
`
`First Use in Commerce Date: 1951-12-18
`
`
`
`ADDITIONAL INFORMATION
`
`(NOT AVAILABLE)
`
`(NOT AVAILABLE)
`
`MADRID PROTOCOL INFORMATION
`
`PROSECUTION HISTORY
`
`2003-02-10 - Third renewal 10 year
`
`2003-02-10 - Section 8 (10-year) acceptedl Section 9 granted
`
`2002-10-25 - Combined Section 8 (10-year)/Section 9 filed
`
`2002-10-25 - Section 9 filed/check record for Section 8
`
`2002-10-25 - PAPER RECEIVED
`
`2002-10-21 - PAPER RECEIVED
`
`1992-10-07 - Second renewal 10 year
`
`1992-08-24 - Section 9 filed/check record for Section 8
`
`1972-10-21 - First renewal
`
`CORRESPONDENCE INFORMATION
`
`Correspondent
`RICHARD A. FRIEDMAN
`PFIZER INC.
`
`http://tarr.uspto.gov/servlet/tarr?regser=serial&entry=71623397
`
`6/27/2006
`
`

`
`Latest Status Info
`
`Page 3 of 3
`
`201 TABOR ROAD
`
`LEGAL DIVISION, 56/2
`MORRIS PLAINS, NJ 07950
`
`http://tarlzuspto.gov/servIet/tarr?regser=serial&entry=71623397
`
`6/27/2006
`
`

`
`Page 9
`
`134 of 192 DOCUMENTS
`
`Copyright 2005 Micromedex, Inc. All Rights Reserved
`Physician's Desk Reference for Non—Prescription Drugs
`
`Sudafed Nasal Decongestant Tab1ets(Pfizer Consumer Healthcare)
`
`BODY:
`
`Drug Facts:
`
`Active Ingredient:
`(in each tablet) Purpose:
`
`Pseudoephedrine HCl
`30 mg .......................... .. Nasal decongestant
`
`Uses:
`
`temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies, and nasal
`congestion associated with sinusitisternporarily relieves sinus congestion and pressure
`
`Warnings:
`
`Do not use if you are now taking a prescription monoarnine oxidase inhibitor (MAO!) (certain drugs for depression,
`psychiatric, or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAO! drug. If you do
`not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product.
`
`Ask a doctor before use if you have:
`
`heart diseasehigh blood pressurethyroid diseasediabetestrouble urinating due to an enlarged prostate gland
`
`When using this product:
`
`do not use more than directed
`
`Stop use and ask a doctor if:
`
`you get nervous, dizzy, or sleeplesssymptoms do not improve within 7 days or are accompanied by fever
`
`If pregnant or breast—feeding, ask a health professional before use.
`
`Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
`
`Directions:
`
`take every 4 to 6 hoursdo not take more than 4 doses in 24 hours
`
`adults and children 12 years of age and over
`children 6 to under 12 years of age
`children under 6 years of age
`
`2 tablets
`1 tablet
`ask a doctor
`
`é'"LexisNexis"
`
`é'"LexisNexis"* é”LexisNexis'"t
`
`

`
`Physician's Desk Reference for Non-Prescription Drugs
`
`Page 10
`
`Other Information:
`
`store at 59 deg.
`
`to 77 deg. F in a dry place
`
`Inactive Ingredients: Acacia, candelilla wax, corn starch, FD&C red no. 40 aluminum lake, FD&C yellow no.
`6 aluminum lake, hypromellose, lactose monohydrate, magnesium stearate, pharmaceutical glaze, poloxamer 407,
`polyethylene glycol, polyethylene oxide, polysorbate 60, povidone, sodium benzoate, sodium lauryl sulfate, stearic
`acid, sucrose, talc, and titanium dioxide. Printed with edible black ink.
`
`Questions? call 1-800-524-2624 (English/Spanish), weekdays, 9 AM — 5 PM EST
`
`How Supplied: Boxes of 24, 48 and 96.
`
`PRODUCT PHOTO(S): NOTE: These photos can be used only for identification by shape, color, and imprint. They
`do not depict actual or relative size.
`
`The product samples shown here have been supplied by the manufacturer and reproduced in full color by PDR as a
`quick—reference identification aid. While every effort has been made to assure accurate reproduction, please remember
`that any visual identification should be considered preliminary.
`In cases of poisoning or suspected overdosage, the
`drug's identity should be verified by chemical analysis.
`See Image
`
`LANGUAGE: ENGLISH
`
`LOAD-DATE: February 11, 2005
`
`é"LexisNexis"
`
`é"'LexisNexis" LexisNexis“
`
`

`
`Latest Status Info
`
`Page 1 of 3
`
`Thank you for your request. Here are the latest results from the TARR web server.
`
`This page was generated by the TARR system on 2006-06-27 20:31:09 ET
`
`Serial Number: 76243487 Agignment Information
`
`Registration Number: 2767460 Assi_g_n_ment Information
`
`Mark (words only): CADUET
`
`Standard Character claim: No
`
`Current Status: Registered.
`
`Date of Status: 2003-09-23
`
`Filing Date: 2001-04-19
`
`Transformed into a National Application: No
`
`Registration Date: 2003-09-23
`
`Register: Principal
`
`Law Office Assigned: LAW OFFICE 115
`
`If you are the applicant or applicant's attorney and have questions about this file, please contact the
`Trademark Assistance Center at TrademarkfissistanceC§nter@g§pto.gog
`
`Current Location: 900 -File Repository (Franconia)
`
`Date In Location: 2003-09-30
`
`
`
`LAST APPLICANT(S)/0WNER(S) OF RECORD
`
`1. CP. PHARMACEUTICALS INTERNATIONAL C.V.
`
`Address:
`
`C.P. PHARMACEUTICALS INTERNATIONAL C.V.
`235 EAST 42ND STREET
`
`NEW YORK, NY 10017
`United States
`
`Legal Entity Type: Limited Partnership
`State or Country Where Organized: Netherlands
`
`GOODS AND/OR SERVICES
`
`International Class: 005
`Class Status: Active
`
`1 http://tarr.uspto.gov/servlet/tarr?regser=serial&entry=76243487
`
`6/27/2006
`
`

`
`Latest Status Info
`
`Page 2 of 3
`
`Pharmaceutical preparations for the treatment of cardiovascular disease
`Basis: 1(a)
`First Use Date: 2003-01-28
`
`First Use in Commerce Date: 2003-01-28
`
`ADDITIONAL INFORMATION
`
`
`(NOT AVAILABLE)
`
`(NOT AVAILABLE)
`
`MADRID PROTOCOL INFORMATION
`
`PROSECUTION HISTORY
`
`2003-09-23 - Registered - Principal Register
`
`2003-07-22 - Allowed for Registration - Principal Register (SOU accepted)
`
`2003-07-22 - Assigned To Examiner
`
`2003-07-21 - Case File In TICRS
`
`2003-06-27 - Statement of use processing complete
`
`2003-03-20 - Amendment to Use filed
`
`2003-03-24 - PAPER RECEIVED
`
`2003-03-10 - Extension 1 granted
`
`2002-11-04 - Extension 1 filed
`
`2002-11-04 — TEAS Extension Received
`
`2002-09-24 - Notice of allowance - mailed
`
`2002-07-02 - Published for opposition
`
`2002-06-12 - Notice of publication
`
`2002-01-30 - Approved for Pub - Principal Register (Initial exam)
`
`2001-10-30 - Communication received from applicant
`
`2001-07-25 - Non-final action mailed
`
`2001-07-24 - Assigned To Examiner
`
`http://tarr.uspto.gov/servlet/tarr‘?regser=serial&entry=76243487
`
`6/27/2006
`
`

`
`Latest Status Info
`
`Page 3 of 3
`
`
`
`CORRESPONDENCE INFORMATION
`
`Correspondent
`Stacey Hallerman (Attorney of record)
`
`STACEY I-IALLERMAN
`PFIZER INC.
`
`235 EAST 42ND STREET
`
`NEW YORK, NEW YORK 10017
`
`Phone Number: (212)-733-4114
`
`http://tarnuspto. gov/servlet/tarr?regser=seriaI&entry=76243487
`
`6/27/2006
`
`

`
`Page 1
`
`32 of 192 DOCUMENTS
`
`Copyright 2006 Micromedex, Inc. All Rights Reserved
`Physician's Desk Reference for Prescription Drugs
`
`Caduet Tablets(Pfizer)
`
`BODY:
`
`DESCRIPTION
`
`CADUET[(R)] (amlodipine besylate and atorvastatin calcium) tablets combine